How to interpret results, recognize signals, and align with current FDA expectations — a practical session on investigation decisions that hold up under regulatory scrutiny.
Includes live access & recording
OOS results test how decisions are made, how information is interpreted, and how well quality systems respond when something does not go as expected.
In many organizations, the initial response to an out-of-specification result follows a familiar path: retesting begins, assumptions are made early, and conclusions are shaped before the full picture is understood. On the surface, the investigation may appear structured. But under closer review, gaps often emerge in how results were evaluated, how potential causes were considered, and how final decisions were justified.
This session takes a closer look at how OOS investigations unfold in practice — from the moment a result is identified to the way conclusions are formed and documented. The focus will be on interpreting results with clarity, recognizing when deeper evaluation is needed, and aligning investigation decisions with current FDA expectations.
Regulatory expectations in this area continue to evolve. Inspectors are no longer focused only on whether an investigation was completed, but on how decisions were made at each step, how scientific reasoning was applied, and whether the outcome reflects a clear and consistent approach.
Subtle signals, overlooked trends, and undocumented assumptions are increasingly becoming points of concern during inspections. A structured-looking investigation that lacks scientific rigor is no longer sufficient.
This session gives you the practical tools to interpret OOS results correctly, document decisions defensibly, and align every step of your investigation with what FDA expects in 2026.
By the end of this session, participants will be equipped to conduct OOS investigations that are thorough, scientifically sound, and fully aligned with current FDA expectations.
Understand how early decisions in an OOS investigation shape the entire outcome and how to avoid premature conclusions.
Recognize meaningful signals, trends, and inconsistencies that require deeper evaluation beyond initial retesting.
Apply structured approaches to distinguish laboratory error from potential process-related causes.
Know when and how to expand an investigation beyond the laboratory into manufacturing and process factors.
Document investigation decisions with clear scientific reasoning that supports defensible conclusions.
Align OOS investigation practices with key principles from 21 CFR Part 211 and current FDA guidance documents.
Four practical focus areas that will sharpen how your team handles OOS results from initial assessment through final documentation.
Learn how the first decisions made after an OOS result is identified shape the entire investigation — and how to avoid assumptions that lead to incomplete or biased conclusions.
Develop the ability to identify meaningful trends, inconsistencies, and signals in OOS data that may not be immediately obvious but are critical to a thorough investigation.
Understand how to structure investigation pathways correctly — including when laboratory-only analysis is insufficient and how to appropriately expand the scope.
Get current on what FDA inspectors are actually looking for in OOS investigations today — beyond completion to scientific rigor, decision traceability, and consistent reasoning.
Six focused areas covering the complete OOS investigation process — from initial assessment through FDA-aligned documentation.
Professionals across quality, manufacturing, laboratory, and regulatory functions in FDA-regulated industries.
Quality Assurance Departments
Quality Control Departments
Manufacturing Departments
Operations Departments
Research & Development
Regulatory Affairs Departments
Compliance Departments
Validation Departments
Technical Services
Auditing / Internal Auditors
Laboratory Analysts
CAPA Coordinators
Site Heads & Directors of Quality
Out-of-specification investigations have long been a focus area for FDA inspectors, but the scrutiny has intensified. The agency's current expectations go well beyond checking whether an investigation was performed — inspectors are examining how decisions were made at each phase, whether scientific reasoning was applied consistently, and whether conclusions are fully supported by documented evidence.
Many organizations continue to rely on investigation approaches that prioritize closure speed over investigative depth. This creates a predictable pattern: retesting begins quickly, a hypothesis is selected early, and the documentation reflects the conclusion rather than the reasoning. While this may satisfy a checklist, it increasingly fails under regulatory review.
The session focuses on investigation decision-making as it actually unfolds in practice — from the initial identification of a result, through the evaluation of possible causes, to the formation and documentation of conclusions. Participants will examine how assumptions enter the investigation process early, how signals are missed or minimized, and how documentation can appear complete while leaving significant gaps in scientific justification.
A strong emphasis is placed on interpretation — understanding what a result actually means before deciding what to do about it. This includes recognizing when a result reflects a genuine quality event versus analytical variability, how to evaluate multiple data points together rather than in isolation, and how to structure the investigation pathway in a way that can be defended during an inspection. Participants will leave with a clearer framework for conducting OOS investigations that meet current FDA expectations and hold up under scrutiny.
Meredith Crabtree has over 30 years of experience in regulated industries, spanning Blood, Plasma, Tissue, Laboratory, Pharma, Medical Device, Cosmetics, Supplements, and Animal Health. Her background encompasses manufacturing, packaging, labelling, and distribution operations across a broad range of regulated environments.
Meredith is the owner of MLKC Consulting, a Quality Consulting firm specializing in product label reviews, third-party inspections, Consent Decree and Recall support. She also performs regulatory assessments and Quality trainings for organizations across FDA-regulated industries.
Don't miss this practical session on OOS investigation decision-making. Learn how to interpret results, recognize signals, and align with FDA expectations for 2026.